ALK, at the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which took part in Spain in Spain from 31 May to 3 June 2024, presented new data from two paediatric phase 3 clinical trials evaluating SQ sublingual immunotherapy (SLIT) tablets in house dust mite (HDM) and tree pollen respiratory allergy. ALK contributed with a total of 18 scientific abstracts within the EAACI 2024 scientific programme - this included findings from two pivotal paediatric phase 3 clinical trials: MT-12: A placebo-controlled phase 3 trial evaluating the efficacy and safety of the SQ HDM SLIT-tablet in children (5-11 years of age) with HDM allergic rhinitis and/or conjunctivitis with or without asthma. TT-06: A placebo-controlled phase3 trial evaluating the efficacy and Safety of the SQ tree SLIT-tablet in Children and adolescents (5-17 years of age) with moderate to severe allergic rhinitis and/or conjunctivitis induced by pollen from birch and trees belonging to the birch homologous group.

The paediatric phase 3 data were presented in four oral abstract presentations during the EAACI Annual Congress by key trial investigators unveiling promising results in treating children by confirming the efficacy and safety of SLIT-tablets in paediatric populations with respiratory allergy caused by HDM or tree pollen (birch homologous group). As part of the EAACI programme, the new phase 3 data were also presented at the ALK symposium which took place on Saturday 1 June, emphasising the clinical importance of these new data. The scientific presentations of the new paediatric phase 3 data demonstrated new clinical evidence documenting the efficacy and safety of the HDM and tree SLIT-tablets in children, by showing reductions in clinical symptoms and medication use, and improved quality of life in the younger children suffering from respiratory allergies.

The SLIT-tablets were generally well-tolerated with a favourable safety profile, similar to the safety profile reported in previous trials. This emphasises the importance of treating allergies in children at an early stage in life and the clinical relevance of developing future treatment strategies for this important age group.